CymaBay Therapeutics Inc. (NASDAQ:CBAY) saw a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 367,834 shares, a decline of 32.6% from the May 31st total of 545,881 shares. Based on an average daily volume of 315,066 shares, the short-interest ratio is presently 1.2 days. Approximately 1.5% of the company’s shares are sold short.

Several institutional investors have recently modified their holdings of CBAY. ClariVest Asset Management LLC bought a new position in shares of CymaBay Therapeutics during the first quarter worth approximately $105,000. Acadian Asset Management LLC bought a new position in shares of CymaBay Therapeutics during the first quarter worth approximately $129,000. TFS Capital LLC bought a new position in shares of CymaBay Therapeutics during the first quarter worth approximately $169,000. Geode Capital Management LLC raised its position in shares of CymaBay Therapeutics by 71.4% in the first quarter. Geode Capital Management LLC now owns 168,528 shares of the biopharmaceutical company’s stock worth $724,000 after buying an additional 70,232 shares during the period. Finally, Renaissance Technologies LLC raised its position in shares of CymaBay Therapeutics by 97.6% in the first quarter. Renaissance Technologies LLC now owns 231,949 shares of the biopharmaceutical company’s stock worth $997,000 after buying an additional 114,549 shares during the period. 36.87% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms have weighed in on CBAY. HC Wainwright reiterated a “buy” rating and set a $7.00 target price (up previously from $6.00) on shares of CymaBay Therapeutics in a report on Monday, March 27th. Piper Jaffray Companies upped their target price on CymaBay Therapeutics from $5.00 to $6.50 and gave the stock an “overweight” rating in a report on Friday, March 24th. Oppenheimer Holdings, Inc. began coverage on CymaBay Therapeutics in a report on Friday, June 23rd. They set an “outperform” rating and a $8.00 target price on the stock. ValuEngine upgraded CymaBay Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Zacks Investment Research downgraded CymaBay Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, April 3rd. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $5.94.

CymaBay Therapeutics (NASDAQ:CBAY) opened at 5.76 on Friday. CymaBay Therapeutics has a 12-month low of $1.15 and a 12-month high of $5.81. The stock’s market cap is $165.61 million. The firm’s 50 day moving average price is $4.59 and its 200-day moving average price is $3.37.

CymaBay Therapeutics (NASDAQ:CBAY) last issued its earnings results on Thursday, May 11th. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.07. The company had revenue of $4.79 million for the quarter. Equities research analysts anticipate that CymaBay Therapeutics will post ($0.79) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Short Interest in CymaBay Therapeutics Inc. (NASDAQ:CBAY) Decreases By 32.6%” was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/07/01/short-interest-in-cymabay-therapeutics-inc-nasdaqcbay-decreases-by-32-6.html.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.